Análisis de la acción Beyond Air Inc (XAIR)XAIRBeyond Air Inc

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Beyond Air Inc (XAIR) is not a good buy right now due to its significant decline in value and poor financial performance. The current price is $4.48, which reflects a staggering year-to-date change of -71.61% and a one-year change of -89.86%. Additionally, the RSI is at 33.255, indicating that the stock is in the oversold territory, but this does not guarantee a rebound. The company also reported a gross margin of only 4.93% in Q4 2026, which is quite low and suggests ongoing profitability challenges. The main risk is the high debt-to-equity ratio of 788.94%, indicating severe financial leverage that could impact future stability and growth.